RPAM
SPRY icon

Rhenman & Partners Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Rhenman & Partners Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-150,000
Closed -$1.5M – 95
2021
Q3 		$1.5M Buy
150,000
+50,000
+50% +$1.23M 0.11% 89
2021
Q2 		$3.09M Buy
+100,000
New +$3.21M 0.21% 87

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Rhenman & Partners Asset Management's SPRY Position: Q4 2021 in Review

Rhenman & Partners Asset Management sold out of ARS Pharmaceuticals (SPRY) in Q4 2021, closing a stake of 150,000 shares — an estimated $1.5M sold.

Rhenman & Partners Asset Management first reported a position in SPRY in Q2 2021 and held it in 2 quarters. The position peaked at $3.09M in Q2 2021. 72 funds tracked by Wall St. Rank hold SPRY as of Q4 2021.

  • Rhenman & Partners Asset Management reported no remaining ARS Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 150,000 ARS Pharmaceuticals shares in Q4 2021, an estimated $1.5M.
  • Rhenman & Partners Asset Management first reported a position in ARS Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Rhenman & Partners Asset Management's ARS Pharmaceuticals position peaked at $3.09M in Q2 2021.
  • 72 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2021.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.